The biopharmaceutical sector has become a significant and growing division of the pharmaceutical industry, with the the top-selling drugs being protein-based products. Mammalian cells, particularly Chinese hamster ovary (CHO) cells, and bacterial systems, such as Escherichia coli (E. coli), produce the bulk of the products on the market but alternative systems such as yeast and plant cells are also used.
Utilizing ABB’s xPAT product,
ABB collaborated with Irish universities and leading biopharmaceutical players in an initiative funded by Enterprise Ireland to construct models to set up and evaluate the benefits of PAT-enabled, model-based control of a fed-batch mammalian cell culture.
There is a wide range of potential applications for models of the mammalian cell culture process: investigation of underlying process mechanisms; analysis and prediction of experimental results facilitating swifter process optimization; advanced control strategies; decision support systems; and soft sensors. Choice of model type depends on both the intended application and also the quantity, quality and nature of experimental data available upon which to build the model.